ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Renata Dobrila Dintinjana, Duška Petranović, Gorazd Pilčič, Vjekoslav Ilijic, Davor Petranović, Marijan Dintinjana
Adenocarcinoma is the most common colon cancer type. This form of colonic neoplasms usually metastasizes initially to regional lymphatic system and through the blood circulation to the lungs and liver, while other forms of expansion and involvement of other o…
Maria Y. Ho, Winson Y. Cheung
The number of long-term colorectal cancer (CRC) survivors has increased substantially over the past three decades due to both ongoing advances in early detection and improvements in cancer therapies. Adult survivors of CRC experience chronic health conditions…
Abdelkarim S. Allal, Arnaud D. Roth, Alessandra Franzetti-Pellanda, Marta Bonet, Pascal Gervaz, Sabine Bieri
Objective: To determine the recommended dose (RD) of gefitinib when combined with concomitant radiotherapy (RT) in a preoperative setting in patients with locally advanced rectal cancer. Secondary objectives were to evaluate acute toxicities, pathological res…
Daniela Rega, Eleonora Cardone, Orlando Catalano, Luca Montesarchio, Ugo Pace, Dario Scala, Giovanni Conzo, Paolo Delrio
Colon cancer rarely combines with abscess of the abdominal wall. We here describe a case treated by extensive surgery, biological mesh abdominal wall repair and negative pressure therapy. A 58-year-old woman presented with a locally advanced right colon cance…
Isac S. F. Lima, Yutaka Yasui, Andrew Scarfe, Marcy Winget
Background: Treatment guidelines in the 1990s established surgery followed by chemoradiotherapy as the standard treatment for stage II/III rectal cancer. Our aim was to investigate the association between the timing of adjuvant treatment and patient survival…
Sigurdis Haraldsdottir, Jeffrey S. Rose, Christina Wu, Lai Wei, Richard M. Goldberg, Tanios Bekaii-Saab
Introduction: Panitumumab is an EGFR inhibitor approved for use in metastatic refractory colorectal cancer. It is unclear whether patients who have progressed on cetuximab may benefit from subsequent panitumumab therapy. This retrospective analysis was conduc…
İlhan Yaylım, Nazlı Ezgi Ozkan, Saime Turan, Gurbet Korkmaz, Yemliha Yıldız, Canan Cacina, Bahar Toptaş, Soykan Arıkan
Programmed cell death called apoptosis, plays an important role in the development and maintenance of tissue homeostasis and abnormalities in apoptotic function have been known as important events in the pathogenesis of many cancer types, such as colorectal c…
Rose Marie Stillie, Heidi L. Sapp, Andrew W. Stadnyk
It has long been appreciated that there is a direct relationship between the intensity and duration of inflammatory bowel diseases (IBD) and increasing intestinal cancer risk but which elements of the inflammatory response are responsible have not been identi…
Pia Osterlund, Päivi Valta, Sören Bondedstam, Leena Lindgren
Background: Chemotherapy in colorectal cancer is usually administered as continuous infusion of 5-fluorouracil, often in combination with oxaliplatin or irinotecan. Targeted drugs are most efficient and tolerable in conjunction with continuous infusion dosing…
Jose Alfredo Reis Neto, Jose Alfredo Reis Junior, Odorino Kagohara, Joaquim Simões Neto, Sérgio O. Banci, Luciane H. Oliveira
Aims: The prognosis on treatment of the cancer of the rectum has not changed in the last fifty years. Survival rates of 50 to 55% seems immutable in several published series. The main cause for those results is the high incidence of recurrence, either local o…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).